TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03901274

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness
Description: The Wellness framework packages together evidence-based practices of family engagement, modular evidence-based practice, quality assurance, and implementation support. Depending on their time of enrollment, participants can be involved in this condition for one to three years. They will be asked to complete assessments during their therapy sessions periodically throughout the trial.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partnership
Description: The two patient-centered enhancements are: enhancing mental health literacy and stigma reduction, and improving family-school-mental health partnerships. Depending on their time of enrollment, participants can be involved in this condition for one to three years. They will be asked to complete assessments during their therapy sessions periodically throughout the trial.
Study: NCT00286728

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive referral to dual-focused self-help
Description: 4 group sessions to introduce patients to dual focused groups
Study: NCT04545749

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-612
Description: UB-612 is a proprietary high-precision designer S1-RBD-protein based vaccine incorporating a Th/CTL epitope peptide pool which could bind to human MHC-I and MHC-II to activate T cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-612
Description: UB-612 is a proprietary high-precision designer S1-RBD-protein based vaccine incorporating a Th/CTL epitope peptide pool which could bind to human MHC-I and MHC-II to activate T cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-612
Description: UB-612 is a proprietary high-precision designer S1-RBD-protein based vaccine incorporating a Th/CTL epitope peptide pool which could bind to human MHC-I and MHC-II to activate T cells.
Study: NCT01404819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthesia with Xenon
Description: Patients undergo anesthesia with xenon (remifentanil with xenon).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard anesthesia
Description: Patients undergo standard anesthesia (remifentanil with propofol)
Study: NCT03340389

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: a ray-tracing aberrometry
Description: The Dysfunctional Lens Index is obtained by a ray-tracing aberrometry
Study: NCT03210558

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone cream 1% (Andro-Feme® )
Description: Testosterone cream 10 mg (1 ml) daily, supplied every evening via a dose applicator to the upper outer thigh for 10 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: Placebo cream (1 ml) daily, supplied every evening via a dose applicator to the upper outer thigh for 10 weeks.
Study: NCT02547181

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Modification
Description: Patient will be provided with tensor bandage and instructed on specific behaviors to prevent movement of the injured part of the hand.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Splint
Description: fibreglass splint
Study: NCT02916186

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Acellular Dermal Matrix
Description: Puros Dermis is a collagenous membrane derived from solvent preserved,human dermis, works as biological scaffold for the new formation of vasculated connective tissue.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Acellular Dermal Matrix
Description: Puros Dermis is a collagenous membrane derived from solvent preserved,human dermis, works as biological scaffold for the new formation of vasculated connective tissue.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tunnel technique with the subepithelial connective tissue graft
Description: Tunnel prepared with the placement of subepithelial connective tissue graft harvested from the palate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tunnel technique with the subepithelial connective tissue graft
Description: Tunnel prepared with the placement of subepithelial connective tissue graft harvested from the palate
Study: NCT01506596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle. Study treatment may continue until disease progression or unacceptable toxicity.
Study: NCT00771758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxycodone IR
Description: maximum daily dose 450 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 5 or 10 mg capsule every 4 - 6 hr as needed for up to 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tapentadol IR
Description: 50 or 75 mg capsule every 4 - 6 hr as needed for up to 10 days
Study: NCT03045744

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: long-term paired associative stimulation
Description: Paired associative stimulation (PAS) administered 3 times per week. PAS comprises transcranial magnetic stimulation (eXimia magnetic stimulator, Nexstim Ltd, Helsinki, Finland) and peripheral nerve stimulation (given with Dantec Keypoint® electroneuromyography device (Natus Medical Incorporated, Pleasanton, CA, USA)).
Study: NCT03310138

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Real Transcranial Magnetic Stimulation
Description: Transcranial magnetic stimulation (TMS) is a minimally invasive brain stimulation technology that can focally stimulate the brain of an awake individual. A localized pulsed magnetic field transmitted through a figure-8 coil (lasting only microseconds) is able to focally stimulate the cortex by depolarizing superficial neurons, which induces electrical currents in the brain. TMS pulses that are delivered repetitively and rhythmically are referred to as repetitive TMS (rTMS). In this study TMS is being delivered with the MagVenture MagPro B60 coil.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Real Transcranial Magnetic Stimulation
Description: Transcranial magnetic stimulation (TMS) is a minimally invasive brain stimulation technology that can focally stimulate the brain of an awake individual. A localized pulsed magnetic field transmitted through a figure-8 coil (lasting only microseconds) is able to focally stimulate the cortex by depolarizing superficial neurons, which induces electrical currents in the brain. TMS pulses that are delivered repetitively and rhythmically are referred to as repetitive TMS (rTMS). In this study TMS is being delivered with the MagVenture MagPro B60 coil.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Transcranial Magnetic Stimulation
Description: The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
Study: NCT03729453

Intervention type: DEVICE
Intervention: SpyGlass
Description: Visualization of main pancreatic duct with SpyGlass catheter.
Study: NCT00829426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam Extended-Release 3 mg Tablets
Description: 1 x 3 mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprazolam Extended-Release 3 mg Tablets
Description: 1 x 3 mg, single dose fasting
Study: NCT04767659

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAMMOT2
Description: Breast cancer patients candidate for neoadjuvant chemotherapy will be evaluated with optical imaging prior to commencement of NAC/baseline, 2-5 days post-NAC, 6-8 days post-NAC, 2 weeks post-NAC, half-way through and on completion of NAC. 2 additional optical evaluations will be carried out on the first 5 patients enrolled, one before breast biopsy and one after the positioning of the metallic clip, in order to evaluate the potential artefacts related to these procedures.
Study: NCT03924661

Intervention type: DEVICE
Intervention: Aortic Valve Replacement
Description: SJM™ Masters Series Hemodynamic Plus (HP) 15mm aortic mechanical heart valve as a replacement device for patients with a diseased, damaged, or malfunctioning aortic valve
Study: NCT03674528

Intervention type: OTHER
Intervention: Magnetic Resonance Elastography (MRE)
Description: The MRE scan will several breath holds and will take approximately 30 minutes to complete.

Intervention type: OTHER
Intervention: Magnetic Resonance Elastography (MRE)
Description: The MRE scan will several breath holds and will take approximately 30 minutes to complete.

Intervention type: DIAGNOSTIC_TEST
Intervention: Liver biopsy
Description: Subjects undergoing WLS will be asked to allow for liver biopsy samples to be collected during their surgical procedure. The collection of these samples will take approximately 5 minutes to complete.
Study: NCT01702207

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Once Daily Tacrolimus
Description: Subjects switched from the tacrolimus twice daily (Prograf®) to the once daily formulation (Advagraf®) to maintain a trough tacrolimus level of 5-8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Twice Daily Tacrolimus
Description: Subjects are kept on Prograf® which is the Twice Daily Tacrolimus
Study: NCT02010892

Intervention type: PROCEDURE
Intervention: Stent Grafting (ESR)

Intervention type: PROCEDURE
Intervention: Open Surgery (OSR)
Study: NCT04857255

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Technology assisted language intervention
Description: speech language therapy that has integrated technology delivered through specific software on an iPad

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: No change will occur to the current ongoing speech-language therapy being delivered.
Study: NCT04471909

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEXUS Aortic Stent Graft System
Description: Arch Stent Graft, whose cranial narrow end is intended to be deployed into the Brachiocephalic artery and whose distal end is intended to be deployed into the Descending Thoracic Aorta.~Ascending Stent Graft intended to be deployed in the Ascending Aorta.~OPTIONAL: Descending Extension can be used in case the aortic lesion elongates further distally and out of the covered length offered by the Arch Stent Graft. Multiple Descending Extensions can be used if needed to cover the entire length of the lesion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEXUS Aortic Stent Graft System
Description: Arch Stent Graft, whose cranial narrow end is intended to be deployed into the Brachiocephalic artery and whose distal end is intended to be deployed into the Descending Thoracic Aorta.~Ascending Stent Graft intended to be deployed in the Ascending Aorta.~OPTIONAL: Descending Extension can be used in case the aortic lesion elongates further distally and out of the covered length offered by the Arch Stent Graft. Multiple Descending Extensions can be used if needed to cover the entire length of the lesion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEXUS Aortic Stent Graft System
Description: Arch Stent Graft, whose cranial narrow end is intended to be deployed into the Brachiocephalic artery and whose distal end is intended to be deployed into the Descending Thoracic Aorta.~Ascending Stent Graft intended to be deployed in the Ascending Aorta.~OPTIONAL: Descending Extension can be used in case the aortic lesion elongates further distally and out of the covered length offered by the Arch Stent Graft. Multiple Descending Extensions can be used if needed to cover the entire length of the lesion.
Study: NCT03497676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Cabotegravir (CAB)
Description: 30 mg tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Cabotegravir (CAB)
Description: 30 mg tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Rilpivirine (RPV)
Description: 25 mg tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Rilpivirine (RPV)
Description: 25 mg tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long-Acting Injectable Cabotegravir (CAB LA)
Description: Administered by intramuscular (IM) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long-Acting Injectable Cabotegravir (CAB LA)
Description: Administered by intramuscular (IM) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long-Acting Injectable Cabotegravir (CAB LA)
Description: Administered by intramuscular (IM) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long-Acting Injectable Rilpivirine (RPV LA)
Description: Administered by intramuscular (IM) injection
Study: NCT01181427

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ABT-267
Description: See arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-267
Description: See arm description

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ABT-267
Description: See arm description

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ABT-267
Description: See arm description

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: See arms description

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: See arms description
Study: NCT03497676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long-Acting Injectable Rilpivirine (RPV LA)
Description: Administered by intramuscular (IM) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long-Acting Injectable Rilpivirine (RPV LA)
Description: Administered by intramuscular (IM) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Antiretroviral Therapy (cART)
Description: Participants will continue their pre-study cART regimen. The antiretroviral drugs in participants' cART regimens were not provided through the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Antiretroviral Therapy (cART)
Description: Participants will continue their pre-study cART regimen. The antiretroviral drugs in participants' cART regimens were not provided through the study.
Study: NCT04515615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab, 200 mg IV for 30-60 min in first day every 3 weeks. Repeated every 21 days. 21 days for a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin: 130 mg/m\^2 IV for 2-6 hour in first day which will be administered at least 30 min after completion of camrelizumab administration, every 3 weeks. Repeated every 21 days, 21 days for a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur gimeracil oteracil potassium capsule
Description: Tegafur gimeracil oteracil potassium capsule: 80 mg/m\^2 twice daily (BID) by continuous oral administration for 14 days, followed by a recovery period of 7 days. Repeated every 21 days. 21 days for a cycle.
Study: NCT02188264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Given PO
Study: NCT03392064

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 119
Description: Investigational, adoptive cellular immunotherapy for the treatment of small cell lung cancer
Study: NCT04377100

Intervention type: BEHAVIORAL
Intervention: Computer task questionnaires
Description: MH COVID-19 Adult, MASQ-SF, STAI, ACS, Hollingshead, DSM XC, PMHC, AUDIT, debriefing questionnaire, and finger-tapping task
Study: NCT05595707

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expert-Guided Early Tracheostomy
Description: Patients judged to be at moderate to high risk of prolonged ventilation(26, 27) were those who had chronic respiratory failure, advanced Effectiveness of an Expert-Guided Early Tracheostomy Pathway Page 6/27 age, thrombocytopenia or coagulopathy, persistent vasopressor shock, requirement for renal replacement therapy, an admission trauma diagnosis amongst other criteria, were included. In the absence of these criteria, a consensus for low risk of prolonged MV was reached. Early PDT, within the first 7 days from intubation, was recommended for patients with a moderate/high risk of prolonged MV (Early Group). Continued MV by ETT was recommend for low-risk patients with the potential for delayed PDT in the event of delayed weaning and liberation (Late Group).
Study: NCT01570413

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No Pelvic Exam
Description: Will not receive pelvic examination.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Examination
Description: Pelvic examination will be performed.
Study: NCT01003808

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMF-001
Description: 100 or 200 mcg, subcutaneously every 2 weeks. Number of Injections: 6 times. (The treatment may be continued if it is beneficial to the subject).
Study: NCT02086175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imprime PGG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study: NCT04678895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Capsule with doses of 1.5mg, 3mg, and 4.5 mg to allow for drug titration. Capsules of different dosages will be indistinguishable to allow for maintenance of blinding.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Capsule with doses of 1.5mg, 3mg, and 4.5 mg to allow for drug titration. Capsules of different dosages will be indistinguishable to allow for maintenance of blinding.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Naltrexone matched placebo capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Naltrexone matched placebo capsule.
Study: NCT05313984

Intervention type: DEVICE
Intervention: Sacral neuromodulation
Description: Sacral neuromodulation: the 2-staged tined lead procedure. (Interstim II therapy, Medtronic).~Stage I: Placement of a tined-lead electrode. 2 - 4 weeks test phase. Stage II: Placement of an implantable pulse generator.
Study: NCT04934800

Intervention type: DRUG
Intervention: Cladribine
Description: No intervention will be administered as a part of this study. Participants who had switched from first-line DMD treatments to treatment with cladribine tablets in routine clinical practice will be assessed for 2 years in this study.
Study: NCT01708408

Intervention type: GENETIC
Intervention: Biomarker studies
Study: NCT04156373

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fuerte
Description: Fuerte is a prevention program targeting youth at risk for psychological trauma who are recent immigrants to the United States. The program is evidence-informed using cognitive-behavioral principles and the Attachment, Regulation, and Competency (ARC) model for treating psychological trauma.
Study: NCT01181427

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: See arms description

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Blood Sample Collection
Description: See arm description

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cytochrome P450 inhibitor
Description: See arm description
Study: NCT02133118

Intervention type: DRUG
Intervention: individual SUs, insulin, pioglitazone
Study: NCT03562273

Intervention type: RADIATION
Intervention: Quality Of Life Sizing Nomogram
Description: If the participant meets the eligibility criteria of the study, and participant chooses to take part, they will receive the tumor bed boost in 8 Gy in 1 fraction just prior to starting whole breast radiation after joining the study. Treatment to the whole breast will begin within 7-8 days from the TB boost (GammaPodTM) treatment.~The radiation therapy will take approximately 6 weeks to complete. Follow-up visits specifically for this study will continue for one year, although the physician will continue to follow as part of routine care.
Study: NCT04364867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: Single shot Exparel 10cc (133mg) mixed with 10cc of 0.5% Bupivicaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pain Pump
Description: Subject will receive an interscalene block with Ropivicaine 0.5% (20cc), and then a pain pump attached in the Post Anesthesia Care Unit infusing at 4cc/hr. The patient will go home with that device until it runs out.
Study: NCT04335669

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab
Description: Cytotoxic agents.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin, cyclophosphamide, capecitabine, paclitaxel, carboplatin, pembrolizumab
Description: Cytotoxic agents.
Study: NCT02449122

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: interventional therapy
Description: Lung cancer patients received drug interventional therapy using the digital subtraction angiography（DSA.）

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: interventional therapy
Description: Lung cancer patients received drug interventional therapy using the digital subtraction angiography（DSA.）
Study: NCT02437916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 228
Description: AMG 228 will be administered intravenously
Study: NCT00626106

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 479
Description: AMG 479 administered with exemestane or fulvestrant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered with either exemestane or fulvestrant
Study: NCT03971903

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention bias modification
Description: The ABM training task was a variation of the computerized visual dot-probe task. During the training, each session includes 54 neutral-sad word pairs presenting 6 times (6 × 54=324 trials) during 20-minute. Participants received 12 sessions over 4 weeks (1 session every other day). In the active ABMT, 90% of the probes appeared at the neutral position and 10% at the sad position. At the placebo ABMT, 50% of the probes appeared at the neutral position and 50% at the sad position.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention bias modification
Description: The ABM training task was a variation of the computerized visual dot-probe task. During the training, each session includes 54 neutral-sad word pairs presenting 6 times (6 × 54=324 trials) during 20-minute. Participants received 12 sessions over 4 weeks (1 session every other day). In the active ABMT, 90% of the probes appeared at the neutral position and 10% at the sad position. At the placebo ABMT, 50% of the probes appeared at the neutral position and 50% at the sad position.